NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
์ข
๋ชฉ ์ฝ๋ NURO
ํ์ฌ ์ด๋ฆNeuroMetrix Inc
์์ฅ์ผJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
์ง์ ์13
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJul 22
์ฃผ์1000 Winter Street
๋์WALTHAM
์ฆ๊ถ ๊ฑฐ๋์NASDAQ Capital Market Consolidated
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02451
์ ํ17818909989
์น์ฌ์ดํธhttps://www.neurometrix.com/
์ข
๋ชฉ ์ฝ๋ NURO
์์ฅ์ผJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์